IVIG (intravenous immunoglobulin) is a blood product infused into a vein to treat a wide range of immune system disorders. It serves two broad purposes: replacing missing antibodies in people whose immune systems can’t produce enough on their own, and calming an overactive immune system that’s attacking the body’s own tissues. Each bag contains concentrated antibodies pooled from 10,000 to 50,000 healthy blood donors, giving it an enormous diversity of immune protection.
How IVIG Works in the Body
IVIG’s effects depend on the dose and the condition being treated, but the core idea is straightforward: flooding the body with a massive quantity of normal antibodies changes how the immune system behaves. At lower doses, it simply fills in the gaps for people who can’t make enough of their own. At higher doses, it acts as an immune system reset button.
Several mechanisms drive that reset. The infused antibodies occupy receptors on immune cells, essentially blocking the body’s own harmful autoantibodies from latching on and causing damage. IVIG also intercepts inflammatory signaling molecules, shifting the immune environment from an aggressive, attack-oriented state to a calmer one. It suppresses the activity of dendritic cells, which are the immune system’s scouts, reducing the chain reaction that leads to tissue inflammation. It can even divert the complement system, a set of proteins that amplifies immune attacks, away from vulnerable tissues where autoantibodies have already settled.
Replacing Antibodies in Immune Deficiency
The most straightforward use of IVIG is antibody replacement for people with primary immunodeficiency, a group of inherited conditions where the body produces little or no immunoglobulin G (IgG). Without adequate IgG, these individuals face repeated, serious bacterial infections, particularly in the lungs, sinuses, and ears. IVIG gives them the broad antibody coverage their bodies can’t generate.
Patients typically qualify when blood tests show severely low IgG levels, generally below 2 g/L in combination with a history of serious infections. The standard maintenance dose ranges from 0.4 to 0.6 grams per kilogram of body weight, infused every four weeks. The goal is to keep IgG levels above a minimum threshold, and some patients with chronic lung disease need more frequent infusions to stay above that line. For most people on replacement therapy, IVIG is a lifelong treatment. The infusions take several hours, usually in a clinic or infusion center, and patients settle into a rhythm of monthly appointments.
Autoimmune and Inflammatory Conditions
When used as an immune-modulating treatment rather than simple replacement, IVIG is given at higher doses, up to 2 grams per kilogram split over two to five days. This higher dose is what triggers the broad anti-inflammatory effects that make it useful across so many different conditions.
Immune Thrombocytopenia (ITP)
ITP is a condition where the immune system destroys the body’s own platelets, the cells responsible for blood clotting. IVIG is used to rapidly raise platelet counts, particularly when bleeding risk is high or a patient needs surgery. In one large retrospective study, platelet counts roughly doubled after IVIG infusion, rising from an average of 59 to about 113 (measured in billions per liter). Just over half of patients saw a meaningful increase of at least 20 points. The effect is temporary, which makes IVIG more of a rescue treatment in ITP than a long-term solution.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP is a neurological condition where the immune system attacks the protective coating around nerves, leading to progressive weakness, numbness, and difficulty walking. Symptoms develop over weeks to months, with both proximal and distal weakness alongside sensory loss and sometimes a noticeable tremor. Roughly two-thirds of patients improve with IVIG. In clinical trials, about 63% of unselected patients showed substantial benefit. Those with a relapsing pattern responded at even higher rates, around 71%.
The response isn’t always permanent. In one study of 52 patients, about 17% reached full remission after a single five-day course, but 40% needed ongoing pulse infusions, typically repeated every few weeks, to maintain their improvement. Certain factors predict a better outcome: having the disease for less than a year, absent reflexes in the arms, and specific patterns on nerve conduction testing. When all favorable factors are present, the chance of improvement climbs above 90%.
Guillain-Barré Syndrome
Guillain-Barré syndrome (GBS) is the acute cousin of CIDP. It comes on suddenly, often after an infection, and can cause rapid, ascending paralysis. IVIG is one of the first-line treatments, given within the first two weeks of symptom onset to shorten the course of the illness and reduce the severity of nerve damage.
Kawasaki Disease
In children, IVIG is a cornerstone treatment for Kawasaki disease, an inflammatory condition that causes fever, rash, and swelling and can damage the coronary arteries of the heart. Early IVIG treatment significantly reduces the risk of lasting heart complications.
Dermatological Uses
IVIG has gained traction in treating severe skin diseases that don’t respond to standard therapies. Dermatomyositis, an autoimmune condition causing muscle weakness and distinctive skin rashes, shows the strongest evidence: clinical trials report an overall response rate of about 80% at two months, with the best results appearing around four months.
Other skin conditions where IVIG has been used include pemphigus vulgaris and pemphigus foliaceus (blistering diseases of the skin and mucous membranes), bullous pemphigoid, toxic epidermal necrolysis, pyoderma gangrenosum, and severe atopic dermatitis. Most of the evidence for these conditions comes from small, uncontrolled studies rather than large randomized trials. IVIG is typically reserved for cases that have failed other treatments, given its cost and limited supply.
What the Infusion Is Like
A typical IVIG infusion takes anywhere from two to six hours, depending on the dose and how well you tolerate it. The infusion rate usually starts slow and increases gradually. Most people sit in a recliner at an infusion center, though some receive treatment in a hospital setting. For immune-modulating doses, treatment is often given over two to five consecutive days. Replacement therapy follows a more routine monthly schedule.
Common side effects include headache, chills, fatigue, and muscle aches, often during or shortly after the infusion. Slowing the rate usually helps. More serious reactions are rare but can include blood clots, kidney problems, and, in very rare cases, a severe allergic reaction. People with very low or absent IgA levels face a slightly higher risk of anaphylaxis because they can develop antibodies against the trace amounts of IgA present in the product. IgA-depleted formulations exist for these patients.
Why IVIG Supply Is Limited
Because each batch requires plasma from tens of thousands of donors, IVIG is expensive and perpetually in tight supply. The manufacturing process involves collecting plasma at donation centers, pooling it, and then using chemical fractionation to isolate the IgG antibodies while removing potential pathogens. This process takes months from donation to finished product. The reliance on human donors means supply can’t simply be scaled up the way a synthetic drug can, and growing demand across an expanding list of conditions keeps pressure on the global supply chain. This is one reason many hospitals and insurance plans restrict IVIG to conditions with strong clinical evidence supporting its use.